DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $827,365 | +43.0% | 3,335 | +38.3% | 0.03% | +39.1% |
| Q2 2023 | $578,593 | -15.7% | 2,411 | -11.4% | 0.02% | -23.3% |
| Q1 2023 | $686,003 | +21.0% | 2,722 | +27.4% | 0.03% | +11.1% |
| Q4 2022 | $566,885 | -8.7% | 2,136 | -11.1% | 0.03% | -18.2% |
| Q3 2022 | $621,000 | +5.3% | 2,404 | +3.3% | 0.03% | +6.5% |
| Q2 2022 | $590,000 | -14.1% | 2,327 | -0.6% | 0.03% | -8.8% |
| Q1 2022 | $687,000 | -43.4% | 2,341 | -36.6% | 0.03% | -44.3% |
| Q4 2021 | $1,214,000 | +116.0% | 3,691 | +99.8% | 0.06% | +90.6% |
| Q3 2021 | $562,000 | +5.6% | 1,847 | -6.9% | 0.03% | 0.0% |
| Q2 2021 | $532,000 | +29.4% | 1,984 | +8.5% | 0.03% | -3.0% |
| Q1 2021 | $411,000 | +88.5% | 1,828 | +86.5% | 0.03% | +94.1% |
| Q4 2020 | $218,000 | -91.2% | 980 | -91.5% | 0.02% | -92.0% |
| Q3 2020 | $2,486,000 | -3.5% | 11,545 | -20.8% | 0.21% | -11.7% |
| Q2 2020 | $2,577,000 | +24.9% | 14,573 | -2.2% | 0.24% | +6.2% |
| Q1 2020 | $2,063,000 | -9.6% | 14,907 | +0.3% | 0.23% | -10.0% |
| Q4 2019 | $2,281,000 | +8.9% | 14,863 | +2.5% | 0.25% | -1.2% |
| Q3 2019 | $2,095,000 | +1.1% | 14,507 | 0.0% | 0.25% | -5.9% |
| Q2 2019 | $2,073,000 | +9.0% | 14,507 | +0.7% | 0.27% | -2.5% |
| Q1 2019 | $1,902,000 | +337.2% | 14,407 | +241.6% | 0.28% | +274.3% |
| Q4 2018 | $435,000 | +3.6% | 4,217 | +9.2% | 0.07% | 0.0% |
| Q3 2018 | $420,000 | -86.8% | 3,862 | -88.0% | 0.07% | -87.6% |
| Q2 2018 | $3,184,000 | +744.6% | 32,270 | +738.2% | 0.60% | +694.7% |
| Q1 2018 | $377,000 | +5.6% | 3,850 | 0.0% | 0.08% | -2.6% |
| Q4 2017 | $357,000 | +19.4% | 3,850 | +10.3% | 0.08% | +11.6% |
| Q3 2017 | $299,000 | +1.4% | 3,490 | 0.0% | 0.07% | -4.2% |
| Q2 2017 | $295,000 | -1.0% | 3,490 | 0.0% | 0.07% | -2.7% |
| Q1 2017 | $298,000 | +9.6% | 3,490 | 0.0% | 0.07% | +10.4% |
| Q4 2016 | $272,000 | -0.7% | 3,490 | +0.0% | 0.07% | -6.9% |
| Q3 2016 | $274,000 | +2.6% | 3,489 | +31.9% | 0.07% | +2.9% |
| Q2 2016 | $267,000 | +6.4% | 2,646 | 0.0% | 0.07% | +14.8% |
| Q1 2016 | $251,000 | +2.0% | 2,646 | 0.0% | 0.06% | +1.7% |
| Q4 2015 | $246,000 | +10.3% | 2,646 | +1.1% | 0.06% | +13.2% |
| Q3 2015 | $223,000 | – | 2,618 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |